anti-Influenza B, Matrix Protein M1 antibody product blog
Tags: Antibody; Monoclonal Antibody; Influenza B, Matrix Protein M1; anti-Influenza B, Matrix Protein M1 antibody;
The Influenza B, Matrix Protein M1 n/a (Catalog #MBS609160) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Influenza B, Matrix Protein M1 can be used in a range of immunoassay formats including, but not limited to, Suitable for use in ELISA and Western Blot. Other applications not tested.Optimal dilutions to be determined by the researcher. Researchers should empirically determine the suitability of the Influenza B, Matrix Protein M1 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The M1 protein, a 27kDa membrane-binding protein, is the most abundant protein in the virus particle and forms the major structural component of the virion, beneath a lipid envelope containing the viral haemagglutinin and neuraminidase glycoproteins and the M2 ion channel. M1 controls the intracellular trafficking of ribonucleoproteins and is also essential for virus budding. The protein can also dimerise under certain conditions.
Immunogen: Influenza B virus derived from allantoic fluid of 10 day old embryonated eggs. Hybridoma: Sp2/0 myeloma cells with spleen cells from Balb/c mice. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Influenza B, Matrix Protein M1 are readily searchable from our website. Different antibodies against the same target such as Influenza B, Matrix Protein M1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.